Clinical Trial Update: Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical study evaluating HRS-1738 as a PET imaging agent for diagnosing prostate cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• HRS-1738

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: PET Imaging in Patients With Prostate Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING